Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

NCT ID: NCT02496884

Last Updated: 2020-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-26
• Study Completion Date: 2017-07-06

Brief Summary

DS-5565 (mirogabalin) is being studied as treatment for fibromyalgia (FM) pain. Because it is excreted through the kidneys, people who have reduced kidney function will not process the drug as well as with those with normal kidney function, so the dose must be reduced. This study will test two reduced dose levels for both moderately reduced and severely reduced kidney function. The study will test the hypothesis that the drug will be safe and well-tolerated in people who have both fibromyalgia and chronic kidney disease.

Detailed Description

The main objective of the trial is to determine the safety and tolerability of subjects with FM and moderate to severe renal dysfunction during 13 weeks of renally-adjusted dosing of DS-5565 compared to placebo, followed by a short-term (4-week) safety follow-up.

This trial is conducted in accordance with the ethical principles of Good Clinical Practice, according to the International Council for Harmonisation (ICH) Harmonised Tripartite Guidelines. An independent Data Safety Monitoring Board (DSMB) is created to further protect the rights, safety, and well-being of subjects who participate in this study by monitoring their progress and results. The independent DSMB is composed of qualified scientists who are not investigators in the study and not otherwise directly associated with the sponsor.

Additional protection is provided by special monitoring of liver enzyme elevations and liver dysfunction performed by a Hepatic Adjudication Committee (HAC), comprised of three qualified hepatologists who are not investigators in the study and not otherwise directly associated with the sponsor. The HAC completes assessments on an ongoing basis. Adjudication of hepatic events is based on evaluation of electronic case report forms (eCRFs) and source documents, as available, including but not limited to hospital discharge summaries, diagnostic imaging, histopathology, consultation, and laboratory reports.

Conditions

Fibromyalgia

Keywords

chronic kidney disease; . α2δ ligands; mirogabalin; pain relief; kidney metabolism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

M-CKD DS-5565 7.5 mg BID

Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.

Group Type: EXPERIMENTAL

DS-5565

Intervention Type: DRUG

DS-5565 7.5 mg tablet for oral use

S-CKD DS-5565 7.5 mg QD

Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565

Group Type: EXPERIMENTAL

DS-5565

Intervention Type: DRUG

DS-5565 7.5 mg tablet for oral use

Placebo

Intervention Type: DRUG

Placebo tablet for oral use to match DS-5565 7.5 mg tablet

M-CKD Placebo

Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo tablet for oral use to match DS-5565 7.5 mg tablet

S-CKD Placebo

Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo tablet for oral use to match DS-5565 7.5 mg tablet

Interventions

DS-5565

DS-5565 7.5 mg tablet for oral use

Intervention Type: DRUG

Placebo

Placebo tablet for oral use to match DS-5565 7.5 mg tablet

Intervention Type: DRUG

Other Intervention Names

Experimental drug; Mirogabalin; SUB60040; No drug; Placebo comparator

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Able to give written informed consent
• Able to complete patient-reported questionnaires per the Investigator's judgment
• Estimated CrCl between 15-59 mL/min from serum creatinine by the central laboratory using the Cockcroft-Gault equation
• Fibromyalgia meeting American College of Rheumatology criteria for FM:

• Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5 or WPI 3 to 6 and SS scale score ≥ 9,
• Pain in at least 11 of 18 specific tender point sites,
• Symptoms have been present at a similar level for at least 3 months, and
• The subject does not have a disorder that would otherwise explain the pain
• Average Daily Pain Score of ≥ 4 on the 11-point numeric rating scale (NRS) over the 7 days prior to randomization (based on completion of at least 4 daily pain assessments during the 7-day baseline period prior to randomization)
• Women of child bearing potential (WOCBP) must be using adequate methods of contraception to avoid pregnancy during the study and for 4 weeks after study completion.

Exclusion Criteria

• Need for ongoing use of concomitant chronic pain medications or any new non-pharmacological pain management techniques that may confound assessments of efficacy and/or safety, including neurolytic treatments (destruction of nerves by chemicals, heat, cold) or surgery, intrathecal pumps, spinal cord stimulators or psychological support within the previous year. Also excluded: topical capsaicin within 6 months; or systemic corticosteroids within 3 months of baseline period.
• Unable to undergo pre-study washout of prohibited concomitant medications
• Subjects with recent history (i.e., within 1 year prior to screening) of alcohol abuse or illicit drug use (cocaine, heroin, marijuana [including medical, prescribed], etc.)
• Use of any selective serotonin reuptake inhibitor (SSRI), unless the subject has been on a stable dose for ≥ 90 days prior to screening and is not anticipated to need any dose adjustment during the course of the study
• Subjects with severe or uncontrolled depression that, in the judgment of the Investigator, makes the subject inappropriate for entry into the study
• Significant neurological or psychiatric disorder unrelated to neuropathic pain
• Other severe pain (eg, sciatica, rheumatoid arthritis) that might impair the assessment of neuropathic pain
• CrCl ≥ 60 mL/min estimated from serum creatinine by the central laboratory using the Cockcroft-Gault equation.
• Subjects who are on hemodialysis or who require hemodialysis before the follow-up assessment; acute renal failure; history of kidney transplant
• Any history of a malignancy other than basal cell carcinoma within the past 5 years
• Clinically significant unstable neurologic, ophthalmologic, hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease (eg, severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) within 12 months prior to screening
• Pregnancy or breast feeding or intent to become pregnant during the study period
• Known hypersensitivity to α2δ ligands or other components of the study medications. Note: Prior exposure to DS-5565 is allowed, as long as hypersensitivity to DS-5565 was not observed.
• Clinically significant ECG abnormalities at the Screening Visit
• Subjects who are at risk of suicide, as defined by their responses to the C-SSRS or in the opinion of the Investigator. Note: Subjects answering "yes" to any of the questions about active suicidal ideation/intent/behaviors that occurred within the past 12 months must be excluded (C-SSRS Suicide Ideation section - Questions 3, 4, or 5; C-SSRS Suicidal Behavior section - any of the suicide behaviors questions). Such subjects should be referred immediately to a mental health professional for appropriate evaluation.
• Subjects who are unlikely to comply with the protocol (eg, uncooperative attitude, inability to return for subsequent visits, and/or otherwise considered by the Investigator to be unlikely to complete the study)
• Subject is currently enrolled in, or it has been fewer than 30 days since ending, another investigational device or drug study or is receiving another investigational agent.
• Subjects who are employees or immediate family of employees of the study site, Sponsor, or contract research organization (CRO)
• Screening laboratory values outside the limits listed in the table below:

• Hematology
• Hemoglobin < 8 g/dL
• Platelet count < 100,000/mm3
• Absolute neutrophil count < 1,500/mm3
• Blood chemistry
• AST > 2.0 × ULN
• ALT > 2.0 × ULN
• Alkaline phosphatase > 1.5 × ULN
• Total bilirubin > 1.2 × ULN (If a subject has total bilirubin >ULN: unconjugated and conjugated bilirubin fractions should be analyzed and only subject documented to have Gilbert's syndrome may be enrolled)
• Creatine kinase > 3.0 × ULN
• Calculated CrCl ≥ 60 mL/min

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Syneos Health

OTHER

Sponsor Role: collaborator

Daiichi Sankyo

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Global Clinical Leader

Role: STUDY_DIRECTOR

Daiichi Sankyo

Locations

Phoenix, Arizona, United States

Colton, California, United States

Los Angeles, California, United States

Santa Ana, California, United States

Colorado Springs, Colorado, United States

Brooksville, Florida, United States

DeBary, Florida, United States

Hialeah, Florida, United States

Kissimmee, Florida, United States

Miami, Florida, United States

Grand Blanc, Michigan, United States

High Point, North Carolina, United States

Cincinnati, Ohio, United States

Wyomissing, Pennsylvania, United States

Greer, South Carolina, United States

Rapid City, South Dakota, United States

Knoxville, Tennessee, United States

Houston, Texas, United States

Plano, Texas, United States

Bellevue, Washington, United States

Charleston, West Virginia, United States

Morgantown, West Virginia, United States

Plovdiv, , Bulgaria

Sevlievo, , Bulgaria

Sofia, , Bulgaria

Stara Zagora, , Bulgaria

Varna, , Bulgaria

Prague, , Czechia

Říčany, , Czechia

Budapest, , Hungary

Nyíregyháza, , Hungary

Elblag, , Poland

Krakow, , Poland

Cluj-Napoca, , Romania

Johannesburg, , South Africa

Pretoria, , South Africa

Barcelona, , Spain

Santiago de Compostela, , Spain

Valencia, , Spain

Countries

United States; Bulgaria; Czechia; Hungary; Poland; Romania; South Africa; Spain

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

2014-003972-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

DS5565-A-U307

Identifier Type: -

Identifier Source: org_study_id